<DOC>
	<DOC>NCT01193608</DOC>
	<brief_summary>This is a study to evaluate the safety of multiple doses of AAB-003 (PF-05236812) in patients with mild to moderate Alzheimer's Disease. Patients will receive either AAB-003 (PF-05236812) or placebo. Each patient's participation will last approximately 41 weeks.</brief_summary>
	<brief_title>Study Evaluating The Safety Of AAB-003 (PF-05236812) In Subjects With Alzheimer's Disease</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<criteria>Diagnosis of probable Alzheimer's Disease with MMSE score of 1626, and brain MRI consistent with the diagnosis of Alzheimer's Disease Concurrent use of cholinesterase inhibitor or memantine allowed, if stable. Caregiver will participate and be able to attend clinic visits with patient Significant neurological disease other than Alzheimer's Disease Major psychiatric disorder Contraindication to undergo brain MRI (e.g., pacemaker, CSF shunt, or foreign metal objects in the body) Women of childbearing potential</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>89 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Randomized</keyword>
	<keyword>Safety Study</keyword>
	<keyword>Adaptive</keyword>
	<keyword>Double Blind</keyword>
</DOC>